# The Effect of Inflammation in Heart Failure

> **NCT05330013** · PHASE2 · WITHDRAWN · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)**

## Conditions studied

- Myocardial Dysfunction
- Heart Failure
- Inflammation

## Interventions

- **DRUG:** Dapagliflozin
- **DEVICE:** MRI scan
- **DEVICE:** CMR imaging

## Key facts

- **NCT ID:** NCT05330013
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-06-23
- **Primary completion:** 2022-06-23
- **Final completion:** 2022-06-23
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** PI left NIH
- **Last updated:** 2022-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05330013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05330013, "The Effect of Inflammation in Heart Failure". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05330013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*